[Intervention of the family physician in the diagnosis of cancer].

Aten Primaria

Unidad Docente de Medicina Familiar, CAP Terrassa Nord, Barcelona.

Published: June 2000

Objective: To find the intervention of family doctors (FD) in diagnosing tumour pathology.

Design: Retrospective descriptive study.

Setting: Urban primary care centre.

Patients: Patients over 14 diagnosed with cancer.

Measurements: Selection of patients from the computerised records between November 1989 and March 1997. Review of clinical histories, analysing: 1. Personal details, 2. Type of cancer, 3. Intervention of the FD in the diagnosis, 4. Symptom of initial consultation, 5. Further tests requested by FD, 6. Interval between consultation and diagnosis, 7. Survival and 8. interval between diagnosis and death. FD intervention in diagnosis was evaluated: 1. Impossible intervention, 2. No intervention, with suspect signs not valued (SSNV) or with suspect signs valued (SSV), 3. Diagnostic intervention, incomplete (Iin) or complete (Ico).

Results: 438 tumours were detected: in 256 men (59%) and 171 women (41%). The most common kind in men was lung cancer (46 cases, 17%), and in women breast cancer (59 cases, 34%). In 233 cases (53%) the intervention of the FD was impossible. In 29 cases (6.5%) the FD's intervention was nil (15 cases with SSNV, 14 cases with SSV). Of the 174 cases (39.6%) in which the FD intervened, full diagnosis was made in 40% (69 cases). The mean of the interval between the first consultation and the diagnosis was significantly less when FD intervention existed, at 1.95 months (CI, 0.63-1.06) in Ico and 2.9 months (CI, 0.51-2.19) in Iin, than when there was no intervention, with delays of 5.58 months (CI, 1.46-3.53) with SSNV and 10.5 months (CI, 8.45-12.54) with SSV (p = 0.000).

Conclusions: The family doctor can play an important part in cancer diagnosis. His/her active intervention can reduce the interval between consultation and diagnosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679573PMC
http://dx.doi.org/10.1016/s0212-6567(00)78619-7DOI Listing

Publication Analysis

Top Keywords

interval consultation
12
consultation diagnosis
12
intervention
11
diagnosis
9
intervention diagnosis
8
suspect signs
8
signs valued
8
cases
8
cancer cases
8
[intervention family
4

Similar Publications

Background: Predicting respiratory complications after pulmonary surgery is important for thoracic surgeons. This study aimed to clarify the relationship between preoperative brain natriuretic peptide (BNP) levels and postoperative respiratory complications (PRC).

Methods: A total of 383 patients with primary or metastatic lung cancer who underwent surgical resection were included in this retrospective study.

View Article and Find Full Text PDF

Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatment.

Am J Ophthalmol Case Rep

March 2025

Ophthalmic Surgeons and Consultants of Ohio, Columbus, OH, USA.

Purpose: To describe a case report of the successful management of necrobiotic xanthogranuloma (NXG), a rare periorbital disease.

Observations: A 61-year-old patient presented with bilateral upper and lower lid lesions which were initially misdiagnosed as xanthelasmas and later confirmed to be NXG. Further investigation also uncovered a diagnosis of multiple myeloma.

View Article and Find Full Text PDF

Background: Adults experiencing homelessness in high income countries often also face issues of problematic substance use, mental ill health, in addition to housing instability, so it is important to understand what interventions might help address these issues. While there is growing evidence of the effectiveness of psychosocial interventions for the general population, limited evidence exists specifically for those experiencing homelessness.

Objectives: To summarise the existing evidence of whether psychosocial interventions work in reducing problematic substance use, mental ill health, and housing instability for adults experiencing homelessness in high income countries.

View Article and Find Full Text PDF

Radiotherapy for oligoprogressive disease in non-small cell lung cancer treated with pembrolizumab in first-line setting: a retrospective study.

Transl Lung Cancer Res

December 2024

Department of Medical Oncology, Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, Paris, France.

Background: Oligoprogression (OP) is common in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs). This study aims to assess the benefit and the safety profile of ablative radiotherapy (RT) for OP in mNSCLC treated with pembrolizumab in first-line setting.

Methods: We retrospectively analyzed records of all consecutive mNSCLC patients who underwent treatment with pembrolizumab (+/- chemotherapy) in first-line setting and developed an OP treated with ablative RT while continuing pembrolizumab, in a French Hospital from 2019 to 2022.

View Article and Find Full Text PDF

Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with mutation-positive metastatic non-small cell lung cancer.

Transl Lung Cancer Res

December 2024

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.

Background: Dabrafenib plus trametinib (Dab + Tram) is an approved targeted therapy in patients with mutated metastatic non-small cell lung cancer (NSCLC). Here, we report the efficacy, safety, and quality of life (QoL) results of Dab + Tram treatment in Chinese patients with mutation-positive metastatic NSCLC.

Methods: This is a single-arm, open-label, multicentre, phase II study (NCT04452877).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!